We propose a minimal protocol for exhaustive genome-wide association interaction analysis that involves screening for epistasis over large-scale genomic data combining strengths of different methods and statistical tools. The different steps of this protocol are illustrated on a real-life data application for Alzheimer's disease (AD) (2259 patients and 6017 controls from France). Particularly, in the exhaustive genome-wide epistasis screening we identified AD-associated interacting SNPs-pair from chromosome 6q11.1 (rs6455128, the KHDRBS2 gene) and 13q12.11 (rs7989332, the CRYL1 gene) (p ¼ 0.006, corrected for multiple testing). A replication analysis in the independent AD cohort from Germany (555 patients and 824 controls) confirmed the discovered epistasis signal (p ¼ 0.036). This signal was also supported by a meta-analysis approach in 5 independent AD cohorts that was applied in the context of epistasis for the first time. Transcriptome analysis revealed negative correlation between expression levels of KHDRBS2 and CRYL1 in both the temporal cortex (b ¼ À0.19, p ¼ 0.0006) and cerebellum (b ¼ À0.23, p < 0.0001) brain regions. This is the first time a replicable epistasis associated with AD was identified using a hypothesis free screening approach.
Introduction
Where does heritability hide? This question frequently arises once heritability is estimated using genetic variants resulting from a genome-wide association study. Genetic variants for human disease traits are either rare with hard to quantify population-based effect sizes, or common, with relatively small or even no individual effects. Arguably, these effects may be masked or enhanced by considering additional genomic loci, in other words, by considering networks of genes (Moore, 2005) . Dependencies among genes in such networks are naturally created by the complexity of gene regulatory and biochemical networks underlying complex diseases q This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). (Templeton, 2000) and are realized as gene-gene interactions (epistasis) (Phillips, 2008) . Therefore, incorporating epistasis in disease association models via genome-wide association interaction (GWAI) studies fits into a systems-level genetics perspective and is an essential step toward a full understanding of biological and biochemical disease mechanisms.
Although many examples of biological gene-gene interactions exist (classical examples of biological epistasis are given in Miko, 2008) , its discovery via statistical analysis methods remains a big challenge. This is in part because of the intrinsic complexity of genetic architectures associated with human complex diseases; architectures that are potentially modified by non-genetic factors as well. Clearly, additional efforts are needed to develop appropriate and clinically relevant models that are able to realistically capture the true underlying biology. Despite the abundance of approaches developed by the epistasis community (Van Steen, 2012) , their success rate in genomewide epistasis studies is fairly low. Ever-returning challenges to take when performing GWAI studies include adequately dealing with multiple testing issues, with multicollinearity induced by correlation patterns between markers, and not in the least, reducing the number of false positive findings. Our experience has shown that only by taking advantages of various methodologies and by examining data rigorously and comprehensively, hereby adopting a protocol that allows the integration of biological knowledge at various levels of the analysis process, the intrinsic low power to detect epistasis signals with currently feasible sample designs can be outweighed.
In this study, we developed a minimal epistasis detection protocol, using genome-wide data and combining strengths of different methods and statistical tools. The proposed protocol comprehensively describes several aspects of data analysis, starting with data quality control and filtering, followed by an analytic part (statistical analysis using a number of available methods for epistasis detection), and ending with a component on biological validation and interpretation of statistical findings. We illustrated this protocol on a real-life data application for Alzheimer's disease (AD) (2259 patients and 6017 controls from France) (Fig. 1) , hereby providing the first epistasis study of this magnitude for AD and showing the advantages of viewing and analyzing data from different angles. As a result, we identified a replicable epistasis signal that contributes to the understanding of AD pathology.
Methods

Study subjects
In this study we used data collections of AD patients and healthy controls (n ¼ 8276) of European ethnicity origin from 3 cities of France: Bordeaux, Dijon, and Montpellier (Table 1) . Details about the ascertainment methods of the cohort (referred to as France_AD), as well as data quality control procedures are described elsewhere (Lambert et al., 2009) .
For replication and meta-analyses, we considered 5 independent case and/or control data (Table 1) . The Flanders-Belgian study cohort (Belgium_AD, n ¼ 2370), was ascertained in the frame of a prospective study of AD, as previously described in Bettens et al. (2010) . Clinical study protocol and the informed consent forms for patient ascertainment were approved by the Ethics Committee of the respective hospitals at the cohort sampling sites in FlandersBelgium. The genetic study protocols and informed consent forms were approved by the Ethics Committees of the University of Antwerp and the University Hospital of Antwerp, Belgium.
The first USA cohort (USA_AD, n ¼ 5697) consisted of Caucasian subjects collected at Mayo Clinic Minnesota in Rochester (574 cases and 2350 controls), Mayo Clinic Florida in Jacksonville (870 cases and 947 controls), or an autopsy-confirmed series from the Brain Bank at Mayo Clinic Florida (586 cases and 370 controls). The characteristics of this cohort were previously described in Allen et al. (2012) . The AD diagnosis of clinical subjects and autopsied AD subjects was made according to NINCDS-ADRDA criteria (McKhann et al., 1984) . All clinical controls had a clinical dementia rating score of 0. All autopsied AD brains had Braak scores of !4.0. Brains used as controls had Braak scores of 2.5 but often had pathologies unrelated to AD. All clinical cases and controls from Mayo Clinic Florida or Minnesota had ages of diagnosis or ages at evaluation !59 years, respectively. All autopsied cases and controls had ages at death !59 years. This study was approved by the appropriate institutional review board and appropriate informed consent was obtained from all participants.
The data for the second USA cohort (USA2_AD, n ¼ 1480), UK (UK_AD, n ¼ 6925), and Germany (Germany_AD, n ¼ 1376) cohorts (USA2_AD, UK_AD, and Germany_AD, respectively) were provided by the Genetic and Environmental Risk for Alzheimer's disease Consortium (Harold et al., 2009 either probable (NINCDS-ADRDA, DSM-IV) or definite (CERAD) AD. All elderly controls, were screened for dementia using the MiniMental State Examination or Alzheimer's Disease Assessment ScaleCognitive, were determined to be free from dementia at neuropathologic examination or had a Braak score of 2.5 or lower. A total of 5235 population controls were included in the 1958 British Birth Cohort (1958BC) (http://www.b58cgene.sgul.ac.uk/), NINDS funded neurogenetics collection at Coriell Cell Repositories (Coriell) (http:// ccr.coriell.org/), the KORA F4 Study Wichmann et al., 2005 , and Heinz Nixdorf Recall Study (Birnbaum et al., 2009; Hillmer et al., 2008) .
Genotyping
The France_AD cohort was genotyped with the with Illumina Human 610-Quad BeadChips. The Belgium_AD cohort was genotyped only for markers rs6455128 and rs7989332 by Sequenom MassARRAY assay using iPLEX Gold chemistry (Sequenom, Hamburg, Germany), followed by MALDI-TOF mass spectrometry. Polymerase chain reaction and extension primers were designed using MassARRAY Assay Design software v3.0.2.0 (Sequenom). Genotypes were called both automatically using MassARRAY Typer software v4.0 (Sequenom) and manually, blinded for disease status. The USA_AD cohort was genotyped only for markers rs6455128 and rs7989332 using TaqMan (Applied Biosystems) technology, according to established protocols. The GERAD samples (USA2_AD, UK_AD, and Germany_AD cohorts) were genotyped by Illumina 610-quad chip (data for 3333 cases and 1225 elderly screened controls) and by Illumina HumanHap550 Beadchip (data for 5235 population controls).
Statistical analysis
The proposed protocol for exhaustive GWAI analysis is summarized in Fig. 1 . In particular, for the France_AD discovery cohort we first applied Hardy-Weinberg disequilibrium (HWE) filtering of SNPs, using c 2 test statistics and a Bonferroni-based nominal significance threshold of 0.05/567589 SNPs ¼ 8.6 Â 10 À8 . SNPs violating HWE in the control group were discarded. Then, we only considered markers with MAF ! 0.05 and call rate !98%, based on the case and/or control samples. Subsequently, omitting mitochondrial and sex chromosome markers, 474,893 SNPs were retained for association analyses. All aforementioned QC steps, as well as main effects association testing (classical trend test, df ¼ 1, additive model) were performed with the SVS Version 7.5 software (Golden Helix, Inc). Before exhaustive genome-wide epistasis screening ( Fig. 1) , the retained 474,893 SNPs were linkage disequilibrium (LD) pruned by considering sliding windows of size 50 (the number of markers used for LD testing at a time) with window increments of 1 marker, and setting the LD r 2 threshold to 0.75 (for any pair of markers under testing whose r 2 > 0.75, the first marker of the pair was discarded), as implemented in SVS Version 7.5. The LD pruning further reduced the number of markers to 312,480 SNPs. For the genome-wide epistasis screening in the selected set of SNPs, we used an adapted version of BOOST (BOolean Operationbased Screening and Testing) (Wan et al., 2010) 48, 821, 718, 960) . The significant SNPpairs were analyzed in more detail using logistic regression analysis in R 2.15.1, allowing the investigation of age (age when the examination of the study participants was conducted), sex, and APOE (apolipoprotein E) AD risk allele (ε4) as potential confounders (model:
, if applicable. Consistency of significant epistasis results was verified by first restoring the LD structure in the genomic regions surrounding the SNPs of a significant pair and by selecting SNPs AE 0.5 Mb upstream and downstream of the SNP pair for follow-up analysis with modelbased multifactor dimensionality reduction (MB-MDR) (Cattaert et al., 2011) version 2.7.5, correcting for main effects as recommended by Mahachie John et al. (2012) and using a permutationbased step-down MaxT approach to control the family-wise error rate to 0.05 (Cattaert et al., 2011) . Unlike BOOST, MB-MDR is an intrinsic nonparametric data mining method that avoids making assumptions about epistasis models and overcomes some of the hurdles of classical regression-based modeling, yet has similar power performances to BOOST (Van Steen, 2012) . We also created synergy disequilibrium plot (Anastassiou, 2007; Watkinson and Anastassiou, 2009) for SNPs, thus appearing in the significant interaction, and 10 upstream and downstream neighboring SNPs. Replication analysis of interesting pairs was based on 5 independent case and/or control data sets, as described previously. The analysis involved logistic regression models assuming a codominant model of inheritance (mimicking BOOST) and accounting for sex, age, and/or APOE only when statistical evidence for their confounding effect was shown (R 2.15.1). Evidence for confounding effects was based on the existence of significant associations with both disease status (AD) and the SNP pair under investigation. In addition, multilocus genotype effect sizes of each of eight 2-locus genotypes versus a reference multilocus genotype (00) were estimated via a multilocus genotype (MLG) association analysis. Here, 0 represents a major allele homozygote, 1 represents a heterozygote, and 2 represents a minor allele homozygote scenarios. MLG is equivalent to a 2-order logistic regression analysis with codominant coding for main effects. To increase the power of the MLG association analysis, we combined the discovery and replication cohorts in a meta-MLG analysis using random effect models (DerSimonian-Laird estimator) or fixed effect models when no evidence for heterogeneity between studies could be detected (assessed by the Q test for heterogeneity; rma function in R library metafor). A smaller meta-analysis based p-value compared with the corresponding discovery cohort based p-value was considered as evidence for replicable epistasis. Finally, to assess the biological role of identified statistical epistasis, we used the IPA software (Ingenuity Systems, Inc). 
Transcriptome analysis
To investigate potential biological interaction between KHDRBS2/CRYL1 gene pair, we evaluated correlation of brain expression levels for these genes. The expression levels were obtained from an autopsied cohort, which was assessed in a recently published brain expression genome-wide association study, DASL microarray expression data. A detailed description of the adopted methodology is given elsewhere (Supplementary Note 2). In these analyses, KHDRBS2 level was the outcome variable and CRYL1 was included as the independent variable. Additional covariates that were included to correct for technical or biological variables were APOE epsilon 4 dosage, age at death, sex, polymerase chain reaction plate, RIN, (RIN À RIN mean) 2 , as well as expression levels of genes that are specific for the main 5 cell types present in the central nervous system, namely ENO2 for neurons (ILMN_1765796), GFAP for astrocytes (ILMN_1697176), CD68 for microglia (ILMN_2267914), OLIG2 for oligodendrocytes (ILMN_1727567), and CD34 for endothelial cells (ILMN_1732799). We also used next-generation RNA sequence (RNAseq) data of temporal cortex expression levels of 94 AD subjects to perform additional correlation analysis between KHDRBS2 and CRYL1. These data are based on 51 base-pair paired end RNAseq performed in triplicate fashion on Illumina HiSeq instruments. We retrieved expression levels of KHDRBS2, CRYL1, as well as the genes used as covariates in the multivariable linear regression models (namely ENO2 for neurons, GFAP for astrocytes, CD68 for microglia, OLIG2 for oligodendrocytes, and CD34 for endothelial cells). For the analysis log2 (gene counts) were used; KHDRBS2 levels were the outcome variable and CRYL1 was included as the independent variable. Additional covariates that were included to correct for technical or biological variables were APOE epsilon 4 dosage, age at death, sex, flow cell, RIN, (RIN À RIN mean) 2 , as well as expression levels of genes that are specific for the main 5 cell types.
Expression quantitative trait loci association analysis
We performed expression quantitative trait loci (eQTL) association analysis (linear regression, additive model) to investigate whether the discovered interacting SNPs, rs6455128, and rs7989332 regulate expression of KHDRBS2 and CRYL1 genes or other genes in the proximity of 1 Mb from them. Analyses were done either in the cerebellum or temporal cortex brain samples of the autopsied AD subjects and non-AD subjects with other pathologies as described previously . In the 2 targeted genomic regions, 20 transcripts (KHDRBS2: NM_152688.1, TPTE2: NM_130785.2, TPTE2: NM_199254.1, MPHOSPH8: NM_017520.2, PSPC1: NR_003272.1, ZMYM5: NM_001039650.1, ZMYM5: NM_001039649.1, GJA3: NM_021954.3, GJB2: NM_004004.4, GJB6: NM_006783.2, CRYL1: NM_015974.2, IFT88: NM_175605.3, IFT88: NM_006531.3, IL17D: NM_138284.1, N6AMT2: NM_174928.1, XPO4: NM_022459.3, LATS2: NM_014572.2, SAP18: NM_005870.3, MRP63: NM_024026.4, and ZDHHC20: NM_153251.2) were detected with a total of 22 probes. Both interacting SNPs were tested for association with the transcript levels measured by these 22 probes in 4 types of analyses: (1) temporal cortex AD subjects only; (2) all temporal cortex samples including AD and non-AD subjects; (3) cerebellum AD subjects only; and (4) all cerebellum samples including AD and non-AD subjects.
Results
Exhaustive genome-wide epistasis screening
The adapted BOOST method (codominant model) applied to the QC-positive and LD-pruned set of markers (312480 SNPs) in the France_AD cohort highlighted 3 significant SNP-SNP interactions with AD. Two of these, rs439401/rs405509 and rs439401/ rs8106922 had associated p-values p Bonferroni-corrected ¼ 1.4 Â 10 
À28
; uncorrected p-values for trend test, df ¼ 1, additive model). When adjusting the analysis for age, sex, and the ε4 AD-risk allele of APOE using logistic regression (codominant model) the identified interactions became insignificant (p Bonferroni-corrected > 0.05 for both interactions). A detailed investigation showed that APOE was mostly responsible for exaggeration of these signals. The third SNP pair significantly associated with AD and identified by BOOST involved rs6455128 (6q11.1, intron of the KHDRBS2 gene) and rs7989332 (13q12.11, intron of the CRYL1 gene) (p Bonferroni-corrected ¼ 0.044). No main effects for these SNPs were detected (rs6455128: p ¼ 0.23, rs7989332: p ¼ 0.66; uncorrected p-values) (Fig. 2, Supplementary  Fig. 1 ). The rs6455128-rs7989332 interaction became even more significant (p Bonferroni-corrected ¼ 0.006) after adjusting it for age, sex, and APOE as before. We restored the LD structure in the regions surrounding rs6455128 and rs7989332 (AE0.5 Mb upstream and downstream) and considered a total of 108 SNPs from 6q11.1 and 219 SNPs from 13q12.11 for a detailed MB-MDR epistasis analysis. MB-MDR gives similar power performances as BOOST but suffers less from harmful multicollinearity (Van Steen et al., 2002) induced by even moderate LD patterns or increased false positive rates because of LD (Moore et al., 2007) . The pair rs6455128/rs7989332 was found to be the only significant interaction identified by MB-MDR in the selected region (p ¼ 0.005; additive model, stepdown MaxT corrected). For additional supporting results see Supplementary Fig. 2. 
Replication analysis for rs6455128 and rs7989332 interaction
Replication analysis for AD-associated SNP pair rs6455128/ rs7989332 was performed using 5 independent case and/or control data sets: from Belgium (Belgium_AD), USA (USA_AD and USA2_AD), UK (UK_AD), and Germany (Germany_AD). In these cohorts, MAFs for rs6455128 and rs7989332 ranged from 0.170 to 0.182 and 0.280 to 0.304, respectively, and no deviations from HWE in controls were observed (Supplementary Table 1 ). Main effect on AD was detected only for rs7989332 (uncorrected p ¼ 0.01) in Belgium_AD cohort. The differences in distributions of the 2-locus genotypes for rs6455128 and rs7989332 in cases and controls in the discovery and replication cohorts are presented in Supplementary Fig. 3 . Whereas the age, sex, and APOE adjusted logistic regression-based p-value for the pair rs6455128/rs7989332 was p ¼ 1.3 Â 10 À13 in the discovery data (France_AD), it was 0.036 in the Germany_AD replication cohort. No significant associations were found in USA_AD, USA2_AD, Belgium_AD, and UK_AD cohorts. Notably, no statistical evidence was found for sex, age (dichotomized by the overall median of 66 years), and APOE to confound the identified interaction in the Germany_AD cohort. These factors did not significantly associate with the multilocus genotype classes of the SNP-pair rs6455128/rs7989332 (p ¼ 0.32 for age and p z 1 for both sex and APOE; performed on 536 cases and 388 controls, for which information about sex, age, and APOE was available).
In line with a composite hypothesis, for which main effects and interaction effects are tested jointly, we performed a MLG association analysis, which quantifies effect sizes of each of 8 multilocus genotypes derived from rs6455128/rs7989332 (0emajor allele homozygote, 1eheterozygote, and 2eminor allele homozygote) versus the reference category (00ehomozygous for the major alleles). In the discovery France_AD cohort, the analysis revealed 4 significant MLG effects (MGL (10) (Fig. 3) .
Transcriptome analysis for the gene-pair KHDRBS2/CRYL1
We investigated associations between brain expression levels (transcriptome analyses) of KHDRBS2 (the probe IDeILMN_1658237) and CRYL1 (the probe IDeILMN_1714397) genes in the autopsied cohort of AD subjects and subjects with other brain pathologies (non-AD subjects) using regression modeling (Table 2, Supplementary  Fig. 4 ). In the DASL microarray expression data, there was significant negative linear association between KHDRBS2 and CRYL1 levels in both the temporal cortex (b ¼ À0.19, p ¼ 0.0006) and cerebellar measurements (b ¼ À0.23, p < 0.0001) from all subjects. When the diagnostic groups were assessed separately, the temporal cortex correlations appeared to be driven by the non-AD subjects (b ¼ À0.32, p ¼ 0.0001), whereas the cerebellar results was significant only in the AD subjects (b ¼ À0.32, p < 0.0001). Nevertheless, the direction of associations was consistent between the AD and non-AD subjects for both brain regions, with overlapping 95% confidence interval for the estimated effect sizes. In the RNAseq data, significant positive correlations between KHDRBS2 and CRYL1 transcripts levels in the temporal cortex of AD subjects were observed.
eQTL association analysis for rs6455128 and rs7989332
The eQTL analysis of the discovered interacting SNPs, rs6455128 and rs7989332, with the expression of KHDRBS2 and CRYL1 transcripts in the temporal or cerebellum brain regions did not show significant association (p-value varied between 0.20e0.89 for rs6455128 and between 0.15e0.97 for rs7989332). Similar analysis in transcripts of genes that reside within 1 Mb from either KHDRBS2 or CRYL1 revealed significant association of the GJB2 NM_004004.4 gene transcript (probe IDeILMN_1769388) with rs7989332 in temporal cortex from the combined set of AD and non-AD subjects (p Bonferroni-corrected ¼ 0.0352). There were also nominally significant associations with temporal cortex levels of this gene in AD subjects only and in cerebellar levels in all subjects including AD and non-AD subjects (Supplementary Table 3 ). Furthermore, levels of another nearby connexin family gene, GJB6, showed nominal associations with rs7989332 in the temporal cortex of AD subjects (Supplementary Table 3 ).
Discussion
AD (OMIM #104300) is a complex, progressive neurodegenerative disease where dementia symptoms gradually worsen over years. The disease is characterized by the neuropathologic findings of neurofibrillary tangles and amyloid plaques that accumulate in vulnerable brain regions (Sennvik et al., 2000) . It is a highly Fig. 3 . Association of MLG(11) of the SNP-pair rs6455128/rs7989332 with AD: results of the fixed effect (RF) meta-analysis in the discovery cohort (France_AD) and 5 replication cohorts (USA_AD, USA2_AD, Belgium_AD, UK_AD, and Germany_AD). FE ModeleFixed effect model; MLG(11)emulti locus genotype for rs6455128 (A/C) and rs7989332 (A/C). Abbreviations: AD, Alzheimer's disease; SNPs, single-nucleotide polymorphisms. heritable genetically heterogeneous disorder with 58%e79% of risk attributed to genetic factors (the most important being related to APOE), possibly modulated by environmental factors (Bettens et al., 2013) . A number of epistasis signals between candidate genes for AD were reported (summarized in Supplementary Table 3) , however, only a few interactions were replicated in independent data. To our knowledge, no exhaustive genome-wide epistasis screening has been conducted for AD before. In this study, we outlined an exhaustive GWAI analysis strategy to identify epistasis with a potential relevant role to AD. Exhaustive epistasis screening revealed the significant ADassociated SNP-SNP interaction rs6455128/rs7989332 (from 6q11.1 and 13q12.11, respectively), that did not appear to be influenced by the potential confounders sex, age, and APOE. This statistically significant interaction effect was also highlighted using replication cohorts and via meta-MLG analysis. The interacting SNPs, rs6455128 and rs7989332, are located in the intronic parts of the KHDRBS2 and CRYL1 genes, respectively.
At one hand, KHDRBS2 (KH domain containing, RNA binding, signal transduction associated 2) is involved in regulation of signal transduction and transcription, and its function has been investigated by studies of its ortholog, Slm1, in Saccharomyces cerevisiae. Slm1, binds signaling molecules, such as phosphatidylinositol 4,5-bisphosphate (PIP2) at the inner plasma membrane. Its activity is regulated by heat stress and it influences downstream cellular events, including modulation of the actin cytoskeleton, and nutrient transport with implications for cell growth and response to stress. Slm1 also interacts with calcineurin and influences sphingolipid metabolism (reviewed in Dickson, 2008) . Thus, changes in levels of KHDRB2 could conceivably influence both levels and functions of many other downstream genes involved in cellular growth and response to stress. Recently, Slm proteins were shown to interact with and activate the kinase complex TORC2 (target of rapamycin kinase 2 complex), as a result of plasma membrane stress by stretching (Berchtold et al., 2012) . Chronic inhibition of the TOR pathway reduced brain amyloid b and cognitive deficits in a mouse model of AD, possibly via upregulation of heatshock proteins (Pierce et al., 2012) . These findings suggest a potential link among KHDRBS2 (Slm1 ortholog), TOR, and heat-shock proteins in AD pathogenesis. On the other hand, the CRYL1 (crystallin, lambda 1) is a structural protein in lens and also has enzymatic activity (catalyzes the dehydrogenation of L-gulonate into dehydro-L-gulonate in the uronate pathway, an alternative glucose metabolic pathway, accounting for about 5% of daily glucose catabolism). Intriguingly, CRYL1 belongs to the family of crystallins, many of which function as small heat-shock proteins involved in stress-protection (Wistow, 2012) . It is therefore tempting to speculate a functional link between KHDRBS2 and CRYL1 along the cellular stress-TOR-heat-shock protein axis.
The fact that we were not able to show significant influence of the discovered variants, rs6455128 and rs7989332, on the expression levels of KHDRBS2 and CRYL1 genes in temporal cortex and cerebellum brain regions does not exclude the possibility of an interaction between these genes that may occur via other mechanisms. Intriguingly, transcriptome analysis of KHDRBS2 and CRYL1 assessed by 2 approaches (DASL microarray data and RNAseq data) revealed nominally significant, though opposite directions for correlations between brain levels of these genes in temporal cortex samples. There could be several explanations for this. First, the negative correlations in the microarray data were observed in all tests, except temporal cortex of AD subjects and cerebellum of non-AD subjects where there was no statistical significance. It is therefore plausible that RNAseq, as a more sensitive approach, is picking up on a correlation that is in the opposite direction in this brain region of ADs compared with other regions and subjects. Temporal cortex is typically one of the most pathologically affected regions in AD. If replicated, such opposing correlations of gene pairs in affected brain regions versus unaffected regions and/or in non-AD subjects could have biologic relevance. Second, it should be kept in mind that our RNAseq analysis assesses whole gene levels whereas DASL expression microarrays measure levels of specific exons and transcripts. Thus, opposing expression changes in the exon (or specific transcript) versus whole gene levels can lead to seemingly contradictory findings between the 2 methods. Future studies should assess non-ADs as well as cerebellum with RNAseq approaches, in addition to comparing specific exon levels with DASL versus other methods. Follow-up functional studies are needed to investigate the relationships between KHDRBS2 and CRYL1.
The discovered interacting variants, rs6455128 and rs7989332, may also influence expression of other genes in close proximity to KHDRBS2 and CRYL1. Particularly, rs7989332 was found to be associated with the expression levels of the GJB2 (gap junction protein, beta 2, 26 kDa) gene transcript. GJB2 is a gene from the connexin family, which resides nearby CRYL1 on chromosome 13. Nominally significant association between GJB2 and CRYL1 levels in temporal cortex of all subjects (AD and non-AD subjects), but not with KHDRBS2 was also found in our study (p ¼ 0.02). These findings suggest that there may be regulatory variants near or within CRYL1, which influence levels of the connexin family genes at this locus. Although this intriguing idea requires replication, we can only guess about its biological relevance to the epistatic variant pair near CRYL1 and KHDRBS2.
Conclusion
This is the first epistasis study of this magnitude for AD. Adopting an exhaustive epistasis analysis strategy using genome-wide SNP data has resulted in identifications of previously unreported SNP-SNP interactions, with plausible biological underpinnings. A replication analysis strategy adapted to the epistasis detection context, as well as a meta-analytic approach, confirmed our findings. These results are promising, given the theoretical sample sizes needed to achieve power levels as they are generally accepted in genome-wide main effects studies. The conducted exhaustive epistasis screening did not confirm previously reported AD-associated epistasis signals (summarized in Supplementary Table 4). We believe that in most cases this is because of an elevated multiple testing burden (data not shown). Also, in the presence of highly complex networks of biochemical processes and genetic heterogeneity, is it really reasonable to assume replication at the marker level? Should replication not be established at the gene and/or pathway level instead? How can standard meta-analysis techniques be adapted to better accommodate nonparametric data-mining approaches for epistasis discovery? How to best perform an epistasis meta-analysis that involves pooling results over studies obtained via quite different analysis techniques, as currently the number of epistasis modeling and testing strategies is still increasing? Therefore, work in progress includes setting user-friendly and theory-supported guidelines for replication analysis and meta-analysis in the context of epistasis screening. Despite the work still ahead, the present work offers a first roadmap for exhaustive epistasis screening efforts and has provided unprecedented leads of biological and clinical importance to AD research.
Disclosure statement
The authors and their institution have no conflicts of interest related to this work. All authors have reviewed the contents of the manuscript being submitted, approved of its contents, and validated the accuracy of the data. The data contained in the manuscript being submitted have not been previously published, have not been submitted elsewhere, and will not be submitted elsewhere while under consideration at Neurobiology of Aging. Appropriate approval and procedures were used concerning human subjects.
